NASDAQ: LGND · Biotechnology
Ligand Pharmaceuticals (LGND) fair value and price range
As of 26 Sep 2026, Faircurve's model values Ligand Pharmaceuticals (LGND) at $302.87 a share. The stock last closed at $302.96, which puts the model's fair value in line with the price. The model grades the evidence behind this valuation as low, so no verdict is shown. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say how likely the fair value is to be right.
Revalued . Price is the close of 2 Oct 2026. Ligand Pharmaceuticals Incorporated.
Faircurve Insights · 26 Sep 2026
Ligand Pharmaceuticals Incorporated operates as a biopharmaceutical entity, primarily engaged in sourcing and advancing technologies to empower pharmaceutical companies globally in their efforts to discover and develop novel therapeutic solutions.
Faircurve's model found a fair value of $302.87 a share on 26 Sep 2026, the midpoint of 2,000 simulations. This fair value moved +6.4% since the previous run on 19 Sep 2026, which gave $284.77. The calibrated range over 63 trading days is $254.10 to $369.29, built from the fair value, and ranges built this way held the price 60% of the time at this horizon. The model grades the evidence behind this valuation as low, so no verdict is shown.
Faircurve's model compares Ligand Pharmaceuticals Incorporated with TG Therapeutics, Inc., Acadia Pharmaceuticals Inc., and Bio-Techne Corporation, each with a fair value of its own on the site. Moves around the last 8 earnings reports, measured from the close before each report to the close after it, were -3.1% on 6 Aug 2026, -3.6% on 14 May 2026, +3.6% on 26 Feb 2026, +6.4% on 6 Nov 2025, +5.4% on 7 Aug 2025, +10.4% on 8 May 2025, +6.3% on 27 Feb 2025, and +3.7% on 7 Nov 2024. The median size, ignoring direction, was 4.6%.
Written from the figures on this page for the 26 Sep 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.
What price range does the model give LGND?
The calibrated range for LGND over 63 trading days is $254.10 to $369.29. There is no live options data for this stock, so the range is built from the fair value and calibrated weekly against realised prices (n = 4,327 past valuations, refreshed 26 Sep 2026). Ranges built this way held the price 60% of the time at this horizon.
The model's own simulated range, from the 20th to the 80th percentile of its runs, is $186.97 to $477.09. In 50% of the simulations the fair value came out above the price the model ran on.
How does LGND compare with similar companies?
The companies in biotechnology closest to Ligand Pharmaceuticals in market value, each on the same model and the same date.
| Company | Last close | Model fair value | Gap | Model verdict |
|---|---|---|---|---|
| PTCT PTC Therapeutics, Inc. | $63.46 | $71.64 | +12.9% | Low evidence grade |
| CYTK Cytokinetics, Incorporated | $65.60 | $55.66 | -15.2% | Low evidence grade |
| TGTX TG Therapeutics, Inc. | $54.29 | $67.07 | +23.5% | Undervalued |
| PTGX Protagonist Therapeutics, Inc. | $140.06 | $142.28 | +1.6% | Data under review |
| ARWR Arrowhead Pharmaceuticals, Inc. | $64.19 | $62.14 | -3.2% | Data under review |
| KRYS Krystal Biotech, Inc. | $322.28 | $387.29 | +20.2% | Low evidence grade |
| ACAD Acadia Pharmaceuticals Inc. | $19.95 | $23.69 | +18.7% | Undervalued |
| TECH Bio-Techne Corporation | $72.40 | $68.12 | -5.9% | Fairly valued |
When does LGND report earnings, and how has the stock reacted?
Ligand Pharmaceuticals's next earnings report is scheduled for 5 Nov 2026. Companies can move their dates.
Options prices on 2 Oct 2026 imply a move of about 5.0% in either direction through the nearest expiry, about 13 days out. That is the size the market is pricing, not a direction.
How LGND moved around its last 8 earnings reports
Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across these 8 reports, ignoring direction, was 4.6%.
| Report date | Two session move |
|---|---|
| 6 Aug 2026 | -3.1% |
| 14 May 2026 | -3.6% |
| 26 Feb 2026 | +3.6% |
| 6 Nov 2025 | +6.4% |
| 7 Aug 2025 | +5.4% |
| 8 May 2025 | +10.4% |
| 27 Feb 2025 | +6.3% |
| 7 Nov 2024 | +3.7% |
Ligand Pharmaceuticals at a glance
Ligand Pharmaceuticals Incorporated operates as a biopharmaceutical entity, primarily engaged in sourcing and advancing technologies to empower pharmaceutical companies globally in their efforts to discover and develop novel therapeutic solutions.
- Market value
- $6.0B
- Sector
- Healthcare
- Industry
- Biotechnology
- Revenue expected, next twelve months
- $361M
- Consensus revenue growth, next fiscal year
- +8.3%
- Analysts with estimates
- 7
- Beta to the US market
- 0.69
- First valued by Faircurve
- 11 Jul 2026
How the fair value is worked out: the model prices Ligand Pharmaceuticals on the value of the whole business, debt included, against the operating profit analysts expect next year (forward EV/EBITDA), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.
What changed in the latest valuation?
On 19 Sep 2026 the model's fair value for LGND was $284.77. As of 26 Sep 2026 it is $302.87, a change of +6.4%. The model revalues every stock it covers each week, and again after an earnings report.
Questions about Ligand Pharmaceuticals's valuation
Is Ligand Pharmaceuticals stock undervalued or overvalued?
Faircurve's model puts LGND's fair value at $302.87 a share against a last close of $302.96, as of 26 Sep 2026. The model grades the evidence behind this valuation as low, so no verdict is shown. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say how likely the fair value is to be right.
What is LGND's fair value?
$302.87 a share as of 26 Sep 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $186.97 to $477.09.
What price range does the model give LGND?
$254.10 to $369.29 over 63 trading days. Ranges built this way held the price 60% of the time across 4,327 past valuations, refreshed 26 Sep 2026.
When does Ligand Pharmaceuticals report earnings next?
The next report is scheduled for 5 Nov 2026. Companies can move their dates.
How much has LGND moved on past earnings reports?
Across its last 8 reports the median two session move was 4.6%, ignoring direction. The largest was +10.4% around the report of 8 May 2025.
How confident is the model in this valuation?
The model's evidence grade for LGND is low. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.